论文部分内容阅读
目的探讨不同组织学类型子宫肉瘤的病理特点及预后影响因素。方法对1993年7月至2013年7月在江苏省肿瘤医院接受治疗的70例子宫肉瘤患者的临床资料进行回顾性分析,探讨多种因素对子宫肉瘤预后的影响及合理的临床治疗方法。结果随访患者2年生存率为77.9%(53/68),5年生存率为50.8%(32/63);临床分期中,Ⅰ期患者的5年生存率为75.9%(22/29),Ⅱ期患者的5年生存率为25.0%(2/8),Ⅲ期患者的5年生存率为18.2%(2/11),Ⅳ期患者5年生存率为5.3%(1/19),差异有统计学意义(P<0.05);平滑肌肉瘤的5年生存率为64.5%,内膜间质肉瘤的5年生存率为51.6%,中胚叶混合瘤的5年生存率为23.1%,三者比较,差异有统计学意义(P<0.05);单纯手术、手术辅助化疗以及手术联合化疗、放疗3种手术方式患者的5年生存率不同,但差异无统计学意义(P>0.05)。结论子宫肉瘤的预后较差,临床表现以阴道流血为主,预后与组织学类型、临床分期、手术方式等有关。
Objective To investigate the pathological characteristics of different histological types of uterine sarcoma and prognostic factors. Methods The clinical data of 70 patients with uterine sarcoma treated in Jiangsu Tumor Hospital from July 1993 to July 2013 were retrospectively analyzed to explore the influence of various factors on the prognosis of uterine sarcoma and reasonable clinical treatment. Results The 2-year survival rate was 77.9% (53/68) and the 5-year survival rate was 50.8% (32/63). The 5-year survival rate of stage Ⅰ patients was 75.9% (22/29) in clinical stage, The 5-year survival rate of stage II patients was 25.0% (2/8), that of stage III patients was 18.2% (2/11), that of stage IV patients was 5.3% (1/19) The difference was statistically significant (P <0.05); 5-year survival rate of leiomyosarcoma was 64.5%, 5-year survival rate of endometrial stromal sarcoma was 51.6%, 5-year survival rate of mixed mesodermal tumor was 23.1% The difference between the three groups was statistically significant (P <0.05). The 5-year survival rates of patients undergoing operation alone, operation adjuvant chemotherapy and operation combined with chemotherapy and radiotherapy were different, but the difference was not statistically significant (P> 0.05) . Conclusion The prognosis of uterine sarcoma is poor, the clinical manifestations of vaginal bleeding, prognosis and histological type, clinical stage, surgical methods and so on.